ARDS Insider Trading Activity and SEC Form 4 Filings
ARDS insider trading summary
No open-market insider purchases or sales of Aridis Pharmaceuticals, Inc. (ARDS) have been reported on SEC Form 4 in the past 12 months.
Latest ARDS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 24, 2024 | Vu Truong | CEO | Buy | $50K (714,286 @ $0.07) |
| Jun 24, 2024 | Eric Patzer | Director | Buy | $50K (714,286 @ $0.07) |
| Sep 7, 2021 | Hasan Jafri | Chief Medical Officer | Buy | $397 (100 @ $3.97) |
| Sep 7, 2021 | Hasan Jafri | Chief Medical Officer | Buy | $8K (1,991 @ $4.15) |
| Sep 3, 2021 | Hasan Jafri | Chief Medical Officer | Buy | $12K (3,009 @ $4.15) |
| Jul 27, 2021 | John F Hamilton | Director | Buy | $10K (2,000 @ $4.87) |
| Jul 27, 2021 | Vu Truong | CEO | Buy | $26K (5,000 @ $5.11) |
| Jul 27, 2021 | Eric Patzer | Director | Buy | $25K (5,175 @ $4.84) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.